Stay updated with breaking news from Transcode Therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Get Rating) was the target of a significant decrease in short interest in March. As of March 15th, there was short interest totalling 263,500 shares, a decrease of 51.3% from the February 28th total of 541,400 shares. Currently, 2.3% of the company’s stock are short sold. Based on an average […]
BOSTON, Feb. 17, 2023 -- TransCode Therapeutics, Inc. , an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the closing of its previously... | February 17, 2023
Snap (SNAP) stock is on the move Wednesday as investors react to the company's earnings report for the fourth quarter of 2022.
/PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of market assessment report on "Global Radiotheranostics Market By radioisotope...
Gainers Ambrx Biopharma Inc. (NYSE:AMAM) shares jumped 551.4% to $2.67 after the company announced preliminary Phase 2 results from its ACE-Brea...